QUOTIENT LIMITED

Franz Walt, CEO

Chris Lindop, CFO

Ed Farrell, President

November 2019 NASDAQ : QTNT

Transforming transfusion diagnostics and beyond

Safe Harbor Statement

This presentation contains forward-looking statements within the meaning of Section

27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act

of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-

looking statements include statements regarding our expectations of continued growth,

the development, regulatory approval, commercialization, and impact of MosaiQ and

other new products (including our current expectations regarding the timing of MosaiQ

project milestones) and forecasts of the demand for MosaiQ Microarrays and our

expected sources of funding. Such statements are based on current assumptions that

involve risks and uncertainties that could cause actual outcomes and results to

differ materially.

These risks and uncertainties, many of which are beyond our control, include delays

or denials of regulatory approvals or clearances for products or applications;

market acceptance of our products; the impact of competition; the impact of facility

expansions and expanded product development, clinical, sales and marketing

activities on operating expenses; delays or other unforeseen problems with respect

to manufacturing, product development or field trial studies; adverse results in

connection with any ongoing or future legal proceeding; continued or worsening

adverse conditions in the general domestic and global economic markets; as well as

the other risks set forth in the company's filings with the Securities and Exchange

Commission (“SEC”). Investors are cautioned not to place undue reliance on these

forward-looking statements, which speak only as of the date hereof. Quotient

disclaims any obligation to update these forward-looking statements.

The Quotient logo and MosaiQ are registered trademarks or trademarks of Quotient

Limited and its subsidiaries in various jurisdictions. Any images, schematics or other

graphic or pictorial representations contained herein, including those representing

the MosaiQ™ Instrument or Microarrays, are for illustrative purposes only. Those

representations may change and may not accurately represent final Quotient products

or services.

This presentation contains statistics and other data that in some cases have been

obtained or compiled from information made available by third parties. Quotient makes

no representation or warranty, expressed or implied, with respect to the accuracy,

reasonableness or completeness of such information.

A shelf registration statement relating to the ordinary shares was filed with the SEC

and is effective. We will also file a prospectus supplement with the Sec for the

offering to which this communication relates. Before you invest, you should read the

prospectus in that registration statement, the prospectus supplement, and other

documents the issuer has filed with the SEC for more complete information about the

issuer and this offering. You may get these documents for free by visiting EDGAR

on the SEC website at www.sec.gov. Alternatively, the issuer, the underwriters, or

any dealer participating in the offering will arrange to send you the prospectus if you

request it by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus

Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at

(877) 547-6340 or by email at prospectus_department@jefferies.com; or Cowen

and Company, LLC, by mail at Cowen and Company, LLC, c/o Broadridge Financial

Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus

Department, or by telephone at (631) 274-2806.

November 2019 2

Quotient

1990: Scottish National Blood Services creates National Reagents Unit

1998: Diagnostics Scotland (later renamed Alba Bioscience)

created from merger of NRU and Scottish Antibody Production Unit

2007: Quotient founded and acquired Alba Bioscience

2014: Quotient Suisse SA formed & Quotient IPO on Nasdaq

2018: MosaiQ factory ISO certified and instrument CE marked

2019: 72 reagent products CE marked and 70 FDA licensed/cleared

Over 30 years’ heritage in transfusion Dx

November 2019 3

Alba by Quotient>$30 million sales growing high single digit

November 2019

‒ Quotient develops and manufactures high quality reagent products for use in transfusion diagnostics

‒ Our reagents are currently used in over 5,000 transfusion labs worldwide every day

‒ 72 reagent products CE marked

‒ 70 FDA licensed/cleared

‒ Product sales from standing orders approximately 70%

4

MosaiQ by Quotient IVD applicationsMosaiQ microarray multiplexing technology suitable for various IVD uses

November 2019

Target segments within the In-Vitro Diagnostics (IVD) market

5An independent consulting firm was engaged to identify opportunities in IVD beyond the transfusion space.

$40bn

IA & MDX in Central lab Plasma Transfusion Patient Transfusion Donor

November 2019

Initial SDS

Expanded IH

Expanded SDS

MDS

IA & MDx in central lab

Commercial plasma

Proof of principal First powerful commercial combination Significant upside sales & profit potential Beyond transfusion Dx

Current focus

Strategic Roadmap

Factory ISO certified - Instrument CE marked - Initial IH microarray CE markedFactory ISO certified - Instrument CE marked - Initial IH microarray CE marked

Future opportunities

Initial focus on Transfusion DX with longer term potential in the broader IVD market

An independent consulting firm was engaged to identify opportunities in IVD beyond the transfusion space.

6

Transfusion Dx MarketAttractive $3.4 billion* market growing low single digit

Patient Testing

Donor Testing

Donor Testing 2/3

SDS: $875m

MDS: $1,100m

IH: $325m

– Concentrated customer base

– High test volume per customer

Patient Testing 1/3

– Fragmented customer base

– Low test volume per customer

IH: $1,100m

*Source: Independent global consulting analysis commissioned by Quotient and Quotient’s own internal analysis

November 2019 7

Transfusion Dx Players Fragmented market with many highly specialized players – MosaiQ has the potential to cover all testing needs

MDS

SDS

Source: Independent global consulting analysis commissioned by Quotient and Quotient’s own internal analysis

IH

November 2019 8

MosaiQ Value Proposition1) One technology for all testing needs

November 2019

Serological

Disease

Screening

Antibody

Screen/ID

Molecular Disease

Screening

Manual

Testing

Blood

grouping

9

MosaiQ Value Proposition1) One technology for all testing needs

November 2019

Manual Testing

MDSExpanded SDS

SDS (CMV & Syphilis)

Blood grouping

MDSSDS

Expanded IH & initial SDS

Blood grouping only

10

MosaiQ Value Proposition2) Automation helps to address shortage of qualified staff

Sources: Number of tests based on Genetic Testing Registry Data in National Center for Biotechnology Information [NCBI], https://www.ncbi.nlm.nih.gov/gtr/

Workforce calculation based on total number of Medical and Clinical Laboratory Technologists and Technicians jobs (Bureau of Labor Statistics [BLS], 2018)

Source: Mounting shortage of medical lab techs hurts most in rural Alberta, expert says 4 April 2017

.

November 2019

300000

315000

330000

345000

360000

375000

10000

20000

30000

40000

50000

60000

2013 2014 2015 2016 2017

Nu

mb

er

of

tests

Wo

rkfo

rce

[…] Canada’s aging population

is creating an increased demand

for lab tests, including blood

and DNA tests.

[…]. But with too few graduates

to fill the positions opening as older

workers retire in the coming years, the

problem is going to get worse,

[…] According to CSMLS, almost

50 per cent of its members

will retire over the next 10 years.

11

*Throughput and footprint based on publicly available data and targeted MosaiQ performance

November 2019

MosaiQ 125

PK 7300

Erytra

Vision MAX

IH 1000

Neo Iris

2,750

2,400

800

690

720

480

1,782

1,491

1,039

527

488

223

MosaiQ Value Proposition3) High throughput and productivity per m²

Company & Instrument Throughput (Tests/h) Productivity (Tests/h)/m2)

Expanded IH

12

MosaiQ Value Proposition3) High throughput and productivity per m²

*Throughput and footprint based on publicly available data and targeted MosaiQ performance

November 2019

Company & Instrument

MosaiQ 125

PRISMnEXT

PK 7300

Cobas e801

Vitros 3600

Architect i400SR

Throughput (Tests/h) Productivity ((Tests/h)/m2)

1,125

960

600

300

189

400

729

490

370

178

100

98

Expanded SDS

Alinity S 600289

13

MosaiQ Value Proposition3) High throughput and productivity per m²

*Throughput and footprint based on publicly available data and targeted MosaiQ performance

November 2019

Company & Instrument

MosaiQ 125

PRISMnEXT

PK 7300

Throughput (Tests/h) Productivity ((Tests/h)/m2)

1,938

800

480

1,256

490

231

Expanded IH + Expanded SDS

Erytra

Neo Iris

Alinity S

14

MosaiQ Value Proposition4) Better workflow leads to better cost position addressing budget constraints

November 2019

Total costs of ownership

Current practice

Direct testing spend

Other testing costs

MosaiQ

€¥

£ $

Total testing cost per donation

Current reagent testing spend

Total testing cost savings

Other testing costs

15

MosaiQ Value Proposition5) We believe comprehensively characterized blood is a better and safer product

November 2019

Standard characterised

bag of blood

Comprehensively characterized

bag of blood

16

MosaiQ Value Proposition6) Individual MDS testing saves time and money

November 2019

Positive

test for

pool

Individual

donor

results

Individual

donor

results

Process with

current industry

standard

1 2 3 4 5 6 7 8

1 2 3

Process with

MosaiQ

17

MosaiQ Debut at ISBT 2019

November 2019

29th Regional ISBT Conference 22nd - 25th June – Basel, Switzerland

2400 attendees

45 customers attended demos

“This proves that the microarray

technology works. It’s no

longer just a vision or dream”

Customer comment in reference

to CE approved MosaiQ system

18

MosaiQ Debut at AABB 2019

November 2019

19th – 22nd October, San Antonio, Texas

3,900 attendees

80 customers attended demos

“It’s good to know that the MosaiQ

system is capable of delivering various

tests at the same time, which would

save labor and time in the lab”

Customer comment in reference

to CE approved MosaiQ system

19

Customer Feedback: EuropeInitial IH hypercare launch

November 2019

“After 2 days, I’m impressed

by the simplicity of the

installation process. Other

companies need one

week or more to manage

the installation”

“Very low level of noise

compared to other

instruments. This is very

important in an open

space where there are

many instruments”

“Time to perform daily

maintenance with

MosaiQ is 30 minutes.

It’s 1 hour or more with

other instruments”

“I’m impressed at how easy

the instrument is to use,

finding menus and routine

task management on the

software is very intuitive”

“Less waste when

compared to

alternative

instruments”

20

Customer Feedback: USInitial SDS field trial

November 2019

“Much less waste

compared to

other instruments”

“It’s a pleasure to work

with a coordinator

and company that is

this well-organized”

“We are impressed by

the quick start-up

and total daily

maintenance time”

“I love this

instrument”

“This is the most user

friendly instrument

I’ve used in my 27

years in the testing

lab”

21

The MosaiQ™ system is now commercially available in Europe. 22

Milestones

– Consolidation on Allan Robb Campus completed

– Publication of successful Expanded IH data

– Initial SDS field trial commenced

January 2019

– Initial SDS EU field trial results published

– Obtained CE mark for first microarray

April 2019

– EU submission of Initial SDS

June 2019

November 2019

– Positive results Initial SDS US field trial

– Publication of positive V&V results for Expanded IH microarray

– Reports positive customer feedback from

European hypercare launch and US field trial sites

– Initiated 3 additional hypercare sites

– Preliminary quarterly revenue higher than guided

October 2019

22

November 2019– Successful equity offering raised $90 million net and

termination of ATM

November 2019

MICROARRAYMULTIPLEXING TECHNOLOGY

23

MosaiQ Microarray Technology

November 2019

IH illustration

Red cell

Antibody

24

Red cell

Detection

Target antibody

MosaiQ Instrument

November 2019

CE marked

Combine sample

and diluent

with microarray

Homogenize

sampleIncubate

Remove

excess sample

Image analysis

antigen typing

Enhancement and

image analysis of

antibody detection

25

Donor Portfolio RoadmapComprehensive donor menu pipeline

3 donor microarrays

November 2019 26

Planned Donor Transfusion Dx Three multiplexed microarrays covering all testing needs

November 2019 27

Expanded IH V&V PerformanceNext step: EU & US field trials

November 2019

Antigen Type A B D C c E e K Cw

Concordance 99.6% 100% 99.3% 99.4% 99.7% 100% 100% 100% 100%

Antigen Type k Kpa Fya Fyb Jka Jkb N S Leb

Concordance 98.9% 99.3% 98.8% 99.7% 98.6% 98.9% 100% 97.7% 98.1%

28

Initial SDS EU & US Field Trial DataNext steps: CE mark approval and FDA 510(k) submission

November 2019

Pathogen Sensitivity % Specificity %

Syphilis 99.4% 99.7%

CMV 99.7% 94.8%

*US field trial performance data

Pathogen Sensitivity % Specificity %

Syphilis 100% 99.6%

CMV 98.7% 97.8%

EU field trial performance data

*Preliminary results

29

MDS Proof of ConceptComing soon...

November 2019

Concept study data expected to be published November 2019

V&V data planned for Q2 CY2021

EU & US field trials planned for Q2 CY2021

30

Next Planned Major Milestones

• MDS proof of concept study

• Initial SDS FDA submission

• Expanded SDS V&V data

• Expanded SDS EU field trials commence

• 510(k) approval for instrument and Initial SDS

• Expanded IH US field trials commence

• Expanded IH CE mark submission

• Expanded IH FDA submission

Outlook next 12 months

November 2019 31

November 2019

FOCUS NOW ON SUSTAINABLEBUSINESS MODEL

32

$451 million of Capital Invested in the Last 8 Years

Source of funds ($m) Use of funds ($m)

$74 million in available cash at end of second quarter

Equity, $387

Debt, $145

Capital & Equipment, $109

R&D MosaiQ Instrument, $26

R&D MosaiQ Microarray, $209

R&D Reagents, $15

Corporate Costs, $48

Debt Service, $44

Increase in cash resources, $81

November 2019 33

Indicative Reagent Spend and Total Cost of TestingSavings in total cost of testing should permit premium pricing

Current Reagent Spend per Donation North America EU

Immunohematological Testing $ 8.00 $ 6.00

Serological Disease Screening $ 12.00 $ 8.00

Molecular Disease Screening $ 15.00 $13.00

November 2019

Total testing cost per donation

Current reagent testing spend

Total testing cost savings

Other testing costs

34

Based on survey of potential customers; presented for illustrative purposes.

Microarray Dollar Unit Cost at 50% yield*Fixed cost leverage and automation drives gross margins

10MM** 60MM

Depreciation Overhead Labor Material

*The information on this page is illustrative, based on management's current estimates as of November 4th , 2019 using assumptions about future cost for MosaiQ microarrays. Such estimates rely significantly on management's judgment and

while presented with numeric specificity and considered reasonable by management, are inherently subject to significant business, economic, competitive, regulatory and other uncertainties and contingencies, all of which are difficult to predict

and many of which are beyond our or any other person's control. There is no guarantee that these estimates will ultimately be realized. If the actual demand for MosaiQ is materially less favorable than shown in this illustration or if the

assumptions used in preparing this illustration provide to be incorrect, the price of our ordinary shares may be adversely affected. See the Safe Harbor Statement included on slide 2.

**MM = Million Microarrays

November 2019 35

Profitability and Cost at Various Microarray Sales Levels*Operating leverage drives profitability

10MM 60MM

COGS Operating Expenses EBIT

Revenue, costs

and EBIT in $

10MM** 60MM**

*The information on this page is illustrative, based on management's current estimates as of November 4th , 2019 using assumptions about future cost for MosaiQ microarrays. Such estimates rely significantly on management's judgment and

while presented with numeric specificity and considered reasonable by management, are inherently subject to significant business, economic, competitive, regulatory and other uncertainties and contingencies, all of which are difficult to predict

and many of which are beyond our or any other person's control. There is no guarantee that these estimates will ultimately be realized. If the actual demand for MosaiQ is materially less favorable than shown in this illustration or if the

assumptions used in preparing this illustration provide to be incorrect, the price of our ordinary shares may be adversely affected. See the Safe Harbor Statement included on slide 2.

**MM = Million microarrays

November 2019 36

Key Takeaways

We built the platform and now we are focused

on menu expansion

Initial attractive commercial combination

expected within the next year in EU

Continue to remain laser focused on delivering

on our business plan

November 2019 37

QUOTIENT MANAGEMENT

November 2019

Speaker bios

38

Franz WaltChief Executive Officer, Quotient

Franz Walt joined Quotient as the company’s Chief Executive Officer

in April 2018. He brings over 30 years of experience in leadership

roles at two of the largest, most influential healthcare companies,

Siemens Healthineers and Roche, and serves as an expert advisor on

the in-vitro diagnostics industry to manufacturing companies and

private equity firms. His career has focused on business turnaround,

above-market growth, profitability improvement, innovation, strategic

alliances, quality, new product introduction, commercialization, media

and investor relationship management.

He served as President of Siemens Healthineers Laboratory

Diagnostics from 2014 to 2017, where he had responsibility for global

P&L and portfolio. In this role he led a turnaround, while bringing to

market the first Siemens-engineered line of diagnostic instruments

branded Atellica® and establishing complementary partnerships to

build a growth portfolio.

During his 23 years at Roche, he held positions of increasing

responsibility in pharma and diagnostics – such as: CEO, Managing

Director and President. The roles were based in various geographic

regions for Roche Diagnostics, and he also served eight years as a

member of the Roche Diagnostics Executive Committee (DiaEC).

Mr. Walt served as a board member of the AdvaMed DX industry

association, where he actively contributed to shape healthcare policy

in diagnostic testing to improve patient health. A Swiss national, he is

fluent in German and English. Mr. Walt also serves as a supervisory

board member of Epigenomics AG (FRA:ECX) since May 2019.

Epigenomics focuses on liquid biopsy tests for the detection of cancer

with their proprietary DNA methylation biomarker technology.

Mr. Walt holds an MBA from City University in Bellevue, Washington

and completed executive programs at Columbia University, IMD,

Switzerland, London Business School and INSEAD, France.

November 2019 39

Ed Farrell

November 2019

President R&D and Manufacturing, Quotient

Edward Farrell joined Quotient (NASDAQ:QTNT) in February 2013

and serves as President of R&D and Manufacturing, overseeing

the product development and manufacturing of MosaiQ™ in

Switzerland and Scotland.

Mr Farrell has over 20 years of engineering, manufacturing and

R&D experience in medical diagnostics in various roles including

several senior positions.

While with Siemens Healthcare Diagnostics, Mr Farrell served

as Managing Director and Vice President with responsibility for R&D

and manufacturing, for a point-of-care diagnostic instruments and

consumables facility, and subsequently, for a high-volume

immunoassay reagent plant in the United Kingdom. Prior experiences

at Siemens include, working in the United States as Director for a

Distribution, Service and Repair site, and as a Senior Manufacturing

Manager in a large diagnostic instrument manufacturing plant in

Ireland. Previously Mr Farrell worked at Ingersoll Rand as a

Production Manager, as Intel Manufacturing Engineer and Supervisor.

Mr Farrell received a BE (Mechanical) and a Masters in Engineering

Science from University College Dublin.

40

Chris LindopChief Financial Officer, Quotient

Chris Lindop joined Quotient (NASDAQ:QTNT) as the company’s

Chief Financial Officer in February 2017.

Mr Lindop has more than 15 years of experience in senior finance

leadership roles with public healthcare companies. He previously

worked as Chief Financial Officer of Haemonetics Corporation

(NYSE:HAE), a global leader in blood processing technology and as

Chief Financial Officer of Inverness Medical Innovations, Inc., a global

developer, manufacturer and marketer of medical diagnostic products.

In addition, Mr Lindop was a non-executive director of Parexel

International Corporation (NASDAQ: PRXL) from 2006, where

he was chairman of the audit and finance committee and a member

of the nominating and governance committee until its sale.

Previously, he served as an audit partner with the Boston office

of Ernst & Young LLP and with the Boston office of Arthur Andersen

LLP. He holds a BA in Business from the University of Strathclyde

(Scotland).

November 2019 41

QUOTIENT LIMITED

Franz Walt, CEO

Chris Lindop, CFO

Ed Farrell, President

November 2019 NASDAQ : QTNT

Transforming transfusion diagnostics and beyond